Jing Hu

Title: Jing Hu: Innovator in Antigenic Epitope Research

Introduction

Jing Hu is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of immunology through his innovative research and patenting of antigenic epitopes. His work focuses on developing peptides that can induce the production of neutralizing antibodies against herpesviruses, particularly Epstein-Barr virus (EBV).

Latest Patents

Jing Hu holds a patent titled "Antigenic epitopes from EBV gp350/220 and uses thereof." This invention relates to a peptide that comprises two domains, each with specific amino acid sequences that exhibit at least 60% sequence similarity to known sequences. The peptide is designed to bind to a monoclonal antibody clone 72A1 and may be useful for immunizing animals against gp350-expressing herpesviruses. The patent highlights the potential for this peptide to detect the presence of neutralizing antibodies in samples, showcasing its relevance in vaccine development.

Career Highlights

Throughout his career, Jing Hu has worked with various organizations, including Valorisation Hsj, Limited Partnership and Valorisation-Recherche, Limited Partnership. His experience in these companies has allowed him to collaborate with other professionals in the field and contribute to advancements in immunological research.

Collaborations

Jing Hu has collaborated with notable colleagues, including Caroline Alfieri and Jurgen Sygusch. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in the scientific community.

Conclusion

Jing Hu's innovative research and patenting of antigenic epitopes represent a significant advancement in the field of immunology. His contributions have the potential to improve vaccine development and enhance our understanding of immune responses to herpesviruses.